Clay B. Siegall
President, Chief Executive Officer and Chairman of the Board, Seattle Genetics
"Our proprietary SEA technology builds on our expertise in empowered, targeted approaches for the treatment of cancer and represents a novel technology…which may lead to improved antitumor immune response."

Our proprietary sugar-engineered antibody (SEA) technology is a novel approach to increasing the potency of monoclonal antibodies that is complementary to our ADC technology.

SEA technology produces a non-fucosylated engineered antibody, resulting in an enhanced innate immune response against cancer. A key feature of our SEA technology is that no genetic modification of the antibody-producing cell line is necessary and standard cell culture conditions can be used, while maintaining the underlying manufacturing processes, yields and product quality. We believe the SEA approach is much simpler and more cost-effective to implement as compared to existing technologies for enhancing antibody effector function, most of which require development of new cell lines.

The first antibody that we have developed using our SEA technology is SEA-CD40. Our preclinical studies show that the non-fucosylated antibody is a potent stimulator of immune cells that may be able to harness the power of a patient’s own immune system to fight their cancer. SEA-CD40 is in a phase 1 trial for advanced solid tumors and lymphoma.